Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors.
Adina BrahaBogdan TimarLaura DiaconuRaluca LupusoruLucian VasilutaAlexandra SimaAdrian VladMircea MunteanuAlin AlbaiDaniela CipuRomulus TimarPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2019)
This study showed the beneficial effect of SGLT 2 inhibitors on EAT after a short period of treatment, but there were no significant changes in the systolic function during the 1st year of study. However, reducing epicardial fat has led to remission of diastolic dysfunction.